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The mitochondrial respiratory chain of the malaria para-
site Plasmodium falciparum differs from that of its
h u m a nh o s ti nt h a ti tl a c k sac a n o n i c a lp r o t o n m o t i v e
NADH:ubiquinone oxidoreductase (Complex I), contain-
ing instead a single sub-unit, non-protonmotive Ndh2,
similar to that found in plant mitochondria, fungi
a n ds o m eb a c t e r i a[ 1 , 2 ] .A ss u c h ,t h eP. falciparum Ndh
2 (PfNdh2) is a potentially attractive anti-malarial
chemotherapeutic target. Using an E.coli NADH dehy-
drogenase knockout strain (ANN0222, ndh::tet nuoB::
nptI-sacRB) we have developed a heterologous expression
system for PfNdh2, facilitating its physicochemical and
enzymological characterisation [2].
PfNdh2 represents a metabolic choke point in the
respiratory chain of P. falciparum mitochondria and is
the focus of a drug discovery programme towards the
development of a novel therapy for uncomplicated
malaria. Here we describe a miniaturised spectrophoto-
metric assay for recombinant PfNdh2 (steady state
NADH oxidation and ubiquinone reduction monitored
at 340 nm and 283 nm respectively) with robust assay
performance measures that has been utilised for the
high throughput screening (HTS) of small molecule
inhibitors.
The objectives of the HTS were twofold: (i) Increase
the number of selective PfNdh2 inhibitors and (ii) to
expand the number of inhibitor chemotypes. At the
time of screening, only one proof of concept molecule,
1-hydroxy-2-dodecyl-4-(1H)quinolone (HDQ), was
known to have PfNdh2 inhibitory activity (IC50=70 nM)
[3,4]. HDQ was used to initiate a primary similarity-
based screen of 1000 compounds from a compound
collection of 750,000 compounds (curated by Biofocus-
DPI). Chemoinformatics methodology was applied to
the hits from this initial phase in order to perform a hit
expansion screen on a further ~16,000 compounds.
Application of this chemoinformatic strategy allowed us
to cover ~16% diversity whilst screening just ~2% of the
compound collection.
The HTS resulted in a hit rate of 0.29% and 1 50
compounds were progressed for potency against
PfNdh2. Of these compounds, 50 were considered active
with IC50s ranging from 100 nM to 40 μM. Currently
seven distinct chemotypes are being progressed from hit
to lead using traditional synthetic medicinal chemistry
strategies.
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